Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05365425
Other study ID # B-2111-720-003
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 1, 2023
Est. completion date December 31, 2026

Study information

Verified date April 2024
Source Seoul National University Bundang Hospital
Contact Soo Lim
Phone +82-31-787-7035
Email limsoo@snu.ac.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized controlled study to assess the effect of choline fenofibrate compared with policosanol in Korean T2DM patients with asymptomatic atherosclerosis.


Description:

In patients with type 2 diabetes with atherosclerotic combined dyslipidemia, the effect of choline fenofibrate on the progression of carotid intima media thickness and carotid artery plaque will be evaluated by 3D carotid ultrasound.


Recruitment information / eligibility

Status Recruiting
Enrollment 56
Est. completion date December 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit - Male or female of 20 years or over - Mixed dyslipidemia: triglyceride 200~499 mg/dL, HDL-cholesterol male =45 mg/dL or female =50 mg/dL - Identified carotid artery plaque: carotid intima-media thickness (cIMT) = 1.0 mm - Creatinine =1.8 mg/dL Exclusion Criteria: - Dyslipidemia which requires other therapy: triglyceride =500 mg/dL or LDL-cholesterol =190 mg/dL - Uncontrolled hypertension - Severe renal dysfunction - GOT/GPT >120/120 or chronic liver disease - Pregnant or childbearing woman who does not have enough contraception - Changes of medication related to chronic diseases (diabetes, hypertension, dyslipidemia, etc.) within 3 months - Other antiplatlet medication such as cilostazol, clopidogrel (except aspirin)

Study Design


Intervention

Drug:
Choline fenofibrate
choline fenofibrate 178.8mg (135mg as fenofibric acid)
Policosanol
policosanol 10mg

Locations

Country Name City State
Korea, Republic of SNUBH Seongnam Gyeonggi

Sponsors (2)

Lead Sponsor Collaborator
Seoul National University Bundang Hospital Daewon Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Carotid intima media thickness Maximum carotid IMT (mm) 24 week
Secondary Area of carotid artery plaque measured by ultrasound 24 week
Secondary Plaque characteristics changes of non-calcified plaque volume (mm3) 24 week
Secondary Glucose homeostasis changes of HbA1c (%) 24 week
Secondary Lipid metabolism TG concentration, HDL-cholesterol concentration 24 week
Secondary Bioelectrical Impedance Analysis Body composition of fat mass (kg) 24 week
Secondary Proteinuria albumin-to-creatinine ratio (mg/g) 24 week
Secondary changes of gut microbiota measured by 16S rRNA or metagenome sequencing, comparing the composition or each phylum/genus/species 24 week
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2